{"disease":{"id":"osteoporosis-in-postmenopausal-women","name":"osteoporosis in postmenopausal women"},"drugs":{"marketed":[{"drug_id":"conjugated-estrogens-bazedoxifene","indication_name":"Treatment of osteoporosis in postmenopausal women at high risk of fracture","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"conjugated-estrogens-bazedoxifene","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05884372","title":"Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Xi'an Honghui Hospital","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}